The estimated Net Worth of Blake E Devitt is at least $1.04 Million dollars as of 21 April 2014. Blake Devitt owns over 4,334 units of Baxter International stock worth over $649,565 and over the last 20 years Blake sold BAX stock worth over $389,242.
Blake has made over 5 trades of the Baxter International stock since 2005, according to the Form 4 filled with the SEC. Most recently Blake sold 4,334 units of BAX stock worth $316,902 on 21 April 2014.
The largest trade Blake's ever made was exercising 10,490 units of Baxter International stock on 5 December 2012 worth over $398,096. On average, Blake trades about 1,208 units every 197 days since 2005. As of 21 April 2014 Blake still owns at least 16,541 units of Baxter International stock.
You can see the complete history of Blake Devitt stock trades at the bottom of the page.
Blake's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney, and Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: